drugset / Trial / NCT05975996
Cyclophosphamide Added to Standard Immunosuppressive Therapy With Herombopag as Front-line Therapy in Patients With Severe Aplastic Anemia
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-center, single-arm, phase 2 study. This study aims to evaluate the efficacy and safety of Anti-lymphocyte globulin plus herombopag in combination with moderate-dose cyclophosphamide for severe aplastic anemia.
Timeline
- Start
- 2023-07-10
- Primary completion
- 2024-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-lymphocyte globulin | Unknown | 25 mg/kg | — |
| Subject | Cyclophosphamide | Other / unclassified | 20 mg/kg | — |
| Subject | RAFUTROMBOPAG | Other / unclassified | 15 mg | — |
| Background | Cyclosporine | Peptide | — | — |